Oral anticoagulant treatment after bioprosthetic valvular intervention or valvuloplasty in patients with atrial fibrillation-A SWEDEHEART study
To describe the prevalence of atrial fibrillation (AF), use of oral anticoagulants (OAC) and change in antithrombotic treatment patterns during follow-up after valve intervention with a biological prosthesis or valvuloplasty. All patients with history of AF or new-onset AF discharged alive after val...
Gespeichert in:
| Veröffentlicht in: | PloS one 2022-01, Vol.17 (1), p.e0262580 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | e0262580 |
| container_title | PloS one |
| container_volume | 17 |
| creator | Christersson, Christina Held, Claes Modica, Angelo Westerbergh, Johan Batra, Gorav |
| description | To describe the prevalence of atrial fibrillation (AF), use of oral anticoagulants (OAC) and change in antithrombotic treatment patterns during follow-up after valve intervention with a biological prosthesis or valvuloplasty.
All patients with history of AF or new-onset AF discharged alive after valvular intervention (biological prosthesis or valvuloplasty) between 2010-2016 in Sweden were included (n = 7,362). Information about comorbidities was collected from national patient registers. Exposure to OAC was based on pharmacy dispensation data. In total 4,800 (65.2%) patients had a history of AF, and 2,562 (34.8%) patients developed new-onset AF, with 999 (39.0%) developing new-onset AF within 3 months after intervention. The proportion of patients with biological valve prosthesis was higher in patients with new-onset AF compared to history of AF (p |
| doi_str_mv | 10.1371/journal.pone.0262580 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2619536127</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A689420256</galeid><doaj_id>oai_doaj_org_article_efd52c420c1f45eea0a15245292f8825</doaj_id><sourcerecordid>A689420256</sourcerecordid><originalsourceid>FETCH-LOGICAL-c729t-e5c1f4f5630a7ba849cddf69127087fdc83990e06e805910d9abad1557659e233</originalsourceid><addsrcrecordid>eNqNk1Fv0zAQxyMEYqPwDRBEQkIg0eI4cWK_IFVbYZUmVdrGeLSuidN6SuPMdjr6KfjKXNZsatAeUB5i-X73t_2_uyB4G5FJFGfR1xvT2hqqSWNqNSE0pYyTZ8FxJGI6TimJnx-sj4JXzt0QwmKepi-Do5gRygQjx8GfhYUqhNrr3MCqrXAVeqvAbxSuoPTKhkttGmucXyukwi1UW-RsqGsMbhHTpg6N7QOmqcD5HUbDBrzGsAvvtF-H4K3Go0q9tLqqoMsaT8PLX7PT2dlsenEVOt8Wu9fBixIqp970_1Hw8_vs6uRsfL74MT-Zno_zjAo_ViyPyqRkaUwgWwJPRF4UZSoimhGelUXOYyGIIqnihImIFAKWUESMZSkTisbxKHi_120q42TvpZM0jQSLU5RBYr4nCgM3srF6A3YnDWh5v2HsSoJFQyolVVkwmieUdJdiSgGBiNGEUUFLzilDrS97LXenmnY5UDvV19N7tbaVSZYxwhH_1l-uXW5UkaOJWKVB1jBS67Vcma3kGctE0t39Uy9gzW2rnJcb7XKFttfKtN0zKSGcRjFB9MM_6NNm9NQK8L26Lg2em3eicppygU-nWItRMHmCwq9QG-yvWpUa9wcJnwcJyHj126-gdU7OLy_-n11cD9mPB-xaQeXXzlRt13RuCCZ7MMcGd1aVjyZHRHZj9uCG7MZM9mOGae8OC_SY9DBX8V8AKiTf</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2619536127</pqid></control><display><type>article</type><title>Oral anticoagulant treatment after bioprosthetic valvular intervention or valvuloplasty in patients with atrial fibrillation-A SWEDEHEART study</title><source>Public Library of Science (PLoS) Journals Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>SWEPUB Freely available online</source><source>Free Full-Text Journals in Chemistry</source><creator>Christersson, Christina ; Held, Claes ; Modica, Angelo ; Westerbergh, Johan ; Batra, Gorav</creator><creatorcontrib>Christersson, Christina ; Held, Claes ; Modica, Angelo ; Westerbergh, Johan ; Batra, Gorav</creatorcontrib><description>To describe the prevalence of atrial fibrillation (AF), use of oral anticoagulants (OAC) and change in antithrombotic treatment patterns during follow-up after valve intervention with a biological prosthesis or valvuloplasty.
All patients with history of AF or new-onset AF discharged alive after valvular intervention (biological prosthesis or valvuloplasty) between 2010-2016 in Sweden were included (n = 7,362). Information about comorbidities was collected from national patient registers. Exposure to OAC was based on pharmacy dispensation data. In total 4,800 (65.2%) patients had a history of AF, and 2,562 (34.8%) patients developed new-onset AF, with 999 (39.0%) developing new-onset AF within 3 months after intervention. The proportion of patients with biological valve prosthesis was higher in patients with new-onset AF compared to history of AF (p<0.001). CHA2DS2-VASc score ≥2 was observed in 83.1% and 75.5% patients with history of AF and new-onset AF, respectively. Warfarin was more frequently dispensed than NOAC at discharge in patients with history of AF (43.9% vs 7.3%), and in patients with new-onset AF (36.6% vs 17.1%). Almost half of the AF population was not dispensed on any OAC at discharge (48.8% in patients with history of AF and 46.3% in patients with new-onset AF).
In this real world study of patients with AF and recent valvular intervention, risk of new-onset AF after valvular intervention is high emphasizing need for frequent rhythm monitoring after intervention. A considerable undertreatment with OAC was observed despite being indicated for the majority of the patients. Warfarin was the OAC most frequently dispensed.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0262580</identifier><identifier>PMID: 35025950</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Administration, Oral ; Aged ; Aged, 80 and over ; Anticoagulants ; Anticoagulants (Medicine) ; Anticoagulants - administration & dosage ; Anticoagulants - pharmacology ; Atrial fibrillation ; Atrial Fibrillation - drug therapy ; Atrial Fibrillation - physiopathology ; Atrial Fibrillation - surgery ; Balloon Valvuloplasty - methods ; Biology and Life Sciences ; Bioprosthesis ; Cardiac arrhythmia ; Cardiology ; Care and treatment ; Codes ; Complications and side effects ; Diabetes ; Disease ; Embolisms ; Engineering and Technology ; Female ; Fibrillation ; Heart attacks ; Heart failure ; Heart Valve Prosthesis ; Humans ; Hypertension ; Intervention ; Male ; Medicine and Health Sciences ; Patient outcomes ; Patients ; Prostheses ; Registries ; Risk Assessment ; Risk Factors ; Stroke ; Stroke - epidemiology ; Sweden ; Thoracic surgery ; Thromboembolism ; Thromboembolism - epidemiology ; Treatment Outcome ; Variables ; Warfarin ; Warfarin - therapeutic use</subject><ispartof>PloS one, 2022-01, Vol.17 (1), p.e0262580</ispartof><rights>COPYRIGHT 2022 Public Library of Science</rights><rights>2022 Christersson et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 Christersson et al 2022 Christersson et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c729t-e5c1f4f5630a7ba849cddf69127087fdc83990e06e805910d9abad1557659e233</citedby><cites>FETCH-LOGICAL-c729t-e5c1f4f5630a7ba849cddf69127087fdc83990e06e805910d9abad1557659e233</cites><orcidid>0000-0001-9116-8084 ; 0000-0002-2480-9547</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757947/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757947/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,550,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79342,79343</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35025950$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-477508$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Christersson, Christina</creatorcontrib><creatorcontrib>Held, Claes</creatorcontrib><creatorcontrib>Modica, Angelo</creatorcontrib><creatorcontrib>Westerbergh, Johan</creatorcontrib><creatorcontrib>Batra, Gorav</creatorcontrib><title>Oral anticoagulant treatment after bioprosthetic valvular intervention or valvuloplasty in patients with atrial fibrillation-A SWEDEHEART study</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>To describe the prevalence of atrial fibrillation (AF), use of oral anticoagulants (OAC) and change in antithrombotic treatment patterns during follow-up after valve intervention with a biological prosthesis or valvuloplasty.
All patients with history of AF or new-onset AF discharged alive after valvular intervention (biological prosthesis or valvuloplasty) between 2010-2016 in Sweden were included (n = 7,362). Information about comorbidities was collected from national patient registers. Exposure to OAC was based on pharmacy dispensation data. In total 4,800 (65.2%) patients had a history of AF, and 2,562 (34.8%) patients developed new-onset AF, with 999 (39.0%) developing new-onset AF within 3 months after intervention. The proportion of patients with biological valve prosthesis was higher in patients with new-onset AF compared to history of AF (p<0.001). CHA2DS2-VASc score ≥2 was observed in 83.1% and 75.5% patients with history of AF and new-onset AF, respectively. Warfarin was more frequently dispensed than NOAC at discharge in patients with history of AF (43.9% vs 7.3%), and in patients with new-onset AF (36.6% vs 17.1%). Almost half of the AF population was not dispensed on any OAC at discharge (48.8% in patients with history of AF and 46.3% in patients with new-onset AF).
In this real world study of patients with AF and recent valvular intervention, risk of new-onset AF after valvular intervention is high emphasizing need for frequent rhythm monitoring after intervention. A considerable undertreatment with OAC was observed despite being indicated for the majority of the patients. Warfarin was the OAC most frequently dispensed.</description><subject>Administration, Oral</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anticoagulants</subject><subject>Anticoagulants (Medicine)</subject><subject>Anticoagulants - administration & dosage</subject><subject>Anticoagulants - pharmacology</subject><subject>Atrial fibrillation</subject><subject>Atrial Fibrillation - drug therapy</subject><subject>Atrial Fibrillation - physiopathology</subject><subject>Atrial Fibrillation - surgery</subject><subject>Balloon Valvuloplasty - methods</subject><subject>Biology and Life Sciences</subject><subject>Bioprosthesis</subject><subject>Cardiac arrhythmia</subject><subject>Cardiology</subject><subject>Care and treatment</subject><subject>Codes</subject><subject>Complications and side effects</subject><subject>Diabetes</subject><subject>Disease</subject><subject>Embolisms</subject><subject>Engineering and Technology</subject><subject>Female</subject><subject>Fibrillation</subject><subject>Heart attacks</subject><subject>Heart failure</subject><subject>Heart Valve Prosthesis</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Intervention</subject><subject>Male</subject><subject>Medicine and Health Sciences</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Prostheses</subject><subject>Registries</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Stroke</subject><subject>Stroke - epidemiology</subject><subject>Sweden</subject><subject>Thoracic surgery</subject><subject>Thromboembolism</subject><subject>Thromboembolism - epidemiology</subject><subject>Treatment Outcome</subject><subject>Variables</subject><subject>Warfarin</subject><subject>Warfarin - therapeutic use</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>D8T</sourceid><sourceid>DOA</sourceid><recordid>eNqNk1Fv0zAQxyMEYqPwDRBEQkIg0eI4cWK_IFVbYZUmVdrGeLSuidN6SuPMdjr6KfjKXNZsatAeUB5i-X73t_2_uyB4G5FJFGfR1xvT2hqqSWNqNSE0pYyTZ8FxJGI6TimJnx-sj4JXzt0QwmKepi-Do5gRygQjx8GfhYUqhNrr3MCqrXAVeqvAbxSuoPTKhkttGmucXyukwi1UW-RsqGsMbhHTpg6N7QOmqcD5HUbDBrzGsAvvtF-H4K3Go0q9tLqqoMsaT8PLX7PT2dlsenEVOt8Wu9fBixIqp970_1Hw8_vs6uRsfL74MT-Zno_zjAo_ViyPyqRkaUwgWwJPRF4UZSoimhGelUXOYyGIIqnihImIFAKWUESMZSkTisbxKHi_120q42TvpZM0jQSLU5RBYr4nCgM3srF6A3YnDWh5v2HsSoJFQyolVVkwmieUdJdiSgGBiNGEUUFLzilDrS97LXenmnY5UDvV19N7tbaVSZYxwhH_1l-uXW5UkaOJWKVB1jBS67Vcma3kGctE0t39Uy9gzW2rnJcb7XKFttfKtN0zKSGcRjFB9MM_6NNm9NQK8L26Lg2em3eicppygU-nWItRMHmCwq9QG-yvWpUa9wcJnwcJyHj126-gdU7OLy_-n11cD9mPB-xaQeXXzlRt13RuCCZ7MMcGd1aVjyZHRHZj9uCG7MZM9mOGae8OC_SY9DBX8V8AKiTf</recordid><startdate>20220113</startdate><enddate>20220113</enddate><creator>Christersson, Christina</creator><creator>Held, Claes</creator><creator>Modica, Angelo</creator><creator>Westerbergh, Johan</creator><creator>Batra, Gorav</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>ACNBI</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>DF2</scope><scope>ZZAVC</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-9116-8084</orcidid><orcidid>https://orcid.org/0000-0002-2480-9547</orcidid></search><sort><creationdate>20220113</creationdate><title>Oral anticoagulant treatment after bioprosthetic valvular intervention or valvuloplasty in patients with atrial fibrillation-A SWEDEHEART study</title><author>Christersson, Christina ; Held, Claes ; Modica, Angelo ; Westerbergh, Johan ; Batra, Gorav</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c729t-e5c1f4f5630a7ba849cddf69127087fdc83990e06e805910d9abad1557659e233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Administration, Oral</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anticoagulants</topic><topic>Anticoagulants (Medicine)</topic><topic>Anticoagulants - administration & dosage</topic><topic>Anticoagulants - pharmacology</topic><topic>Atrial fibrillation</topic><topic>Atrial Fibrillation - drug therapy</topic><topic>Atrial Fibrillation - physiopathology</topic><topic>Atrial Fibrillation - surgery</topic><topic>Balloon Valvuloplasty - methods</topic><topic>Biology and Life Sciences</topic><topic>Bioprosthesis</topic><topic>Cardiac arrhythmia</topic><topic>Cardiology</topic><topic>Care and treatment</topic><topic>Codes</topic><topic>Complications and side effects</topic><topic>Diabetes</topic><topic>Disease</topic><topic>Embolisms</topic><topic>Engineering and Technology</topic><topic>Female</topic><topic>Fibrillation</topic><topic>Heart attacks</topic><topic>Heart failure</topic><topic>Heart Valve Prosthesis</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Intervention</topic><topic>Male</topic><topic>Medicine and Health Sciences</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Prostheses</topic><topic>Registries</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Stroke</topic><topic>Stroke - epidemiology</topic><topic>Sweden</topic><topic>Thoracic surgery</topic><topic>Thromboembolism</topic><topic>Thromboembolism - epidemiology</topic><topic>Treatment Outcome</topic><topic>Variables</topic><topic>Warfarin</topic><topic>Warfarin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Christersson, Christina</creatorcontrib><creatorcontrib>Held, Claes</creatorcontrib><creatorcontrib>Modica, Angelo</creatorcontrib><creatorcontrib>Westerbergh, Johan</creatorcontrib><creatorcontrib>Batra, Gorav</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SWEPUB Uppsala universitet full text</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SWEPUB Uppsala universitet</collection><collection>SwePub Articles full text</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Christersson, Christina</au><au>Held, Claes</au><au>Modica, Angelo</au><au>Westerbergh, Johan</au><au>Batra, Gorav</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oral anticoagulant treatment after bioprosthetic valvular intervention or valvuloplasty in patients with atrial fibrillation-A SWEDEHEART study</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2022-01-13</date><risdate>2022</risdate><volume>17</volume><issue>1</issue><spage>e0262580</spage><pages>e0262580-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>To describe the prevalence of atrial fibrillation (AF), use of oral anticoagulants (OAC) and change in antithrombotic treatment patterns during follow-up after valve intervention with a biological prosthesis or valvuloplasty.
All patients with history of AF or new-onset AF discharged alive after valvular intervention (biological prosthesis or valvuloplasty) between 2010-2016 in Sweden were included (n = 7,362). Information about comorbidities was collected from national patient registers. Exposure to OAC was based on pharmacy dispensation data. In total 4,800 (65.2%) patients had a history of AF, and 2,562 (34.8%) patients developed new-onset AF, with 999 (39.0%) developing new-onset AF within 3 months after intervention. The proportion of patients with biological valve prosthesis was higher in patients with new-onset AF compared to history of AF (p<0.001). CHA2DS2-VASc score ≥2 was observed in 83.1% and 75.5% patients with history of AF and new-onset AF, respectively. Warfarin was more frequently dispensed than NOAC at discharge in patients with history of AF (43.9% vs 7.3%), and in patients with new-onset AF (36.6% vs 17.1%). Almost half of the AF population was not dispensed on any OAC at discharge (48.8% in patients with history of AF and 46.3% in patients with new-onset AF).
In this real world study of patients with AF and recent valvular intervention, risk of new-onset AF after valvular intervention is high emphasizing need for frequent rhythm monitoring after intervention. A considerable undertreatment with OAC was observed despite being indicated for the majority of the patients. Warfarin was the OAC most frequently dispensed.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>35025950</pmid><doi>10.1371/journal.pone.0262580</doi><tpages>e0262580</tpages><orcidid>https://orcid.org/0000-0001-9116-8084</orcidid><orcidid>https://orcid.org/0000-0002-2480-9547</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2022-01, Vol.17 (1), p.e0262580 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2619536127 |
| source | Public Library of Science (PLoS) Journals Open Access; MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; SWEPUB Freely available online; Free Full-Text Journals in Chemistry |
| subjects | Administration, Oral Aged Aged, 80 and over Anticoagulants Anticoagulants (Medicine) Anticoagulants - administration & dosage Anticoagulants - pharmacology Atrial fibrillation Atrial Fibrillation - drug therapy Atrial Fibrillation - physiopathology Atrial Fibrillation - surgery Balloon Valvuloplasty - methods Biology and Life Sciences Bioprosthesis Cardiac arrhythmia Cardiology Care and treatment Codes Complications and side effects Diabetes Disease Embolisms Engineering and Technology Female Fibrillation Heart attacks Heart failure Heart Valve Prosthesis Humans Hypertension Intervention Male Medicine and Health Sciences Patient outcomes Patients Prostheses Registries Risk Assessment Risk Factors Stroke Stroke - epidemiology Sweden Thoracic surgery Thromboembolism Thromboembolism - epidemiology Treatment Outcome Variables Warfarin Warfarin - therapeutic use |
| title | Oral anticoagulant treatment after bioprosthetic valvular intervention or valvuloplasty in patients with atrial fibrillation-A SWEDEHEART study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T21%3A20%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oral%20anticoagulant%20treatment%20after%20bioprosthetic%20valvular%20intervention%20or%20valvuloplasty%20in%20patients%20with%20atrial%20fibrillation-A%20SWEDEHEART%20study&rft.jtitle=PloS%20one&rft.au=Christersson,%20Christina&rft.date=2022-01-13&rft.volume=17&rft.issue=1&rft.spage=e0262580&rft.pages=e0262580-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0262580&rft_dat=%3Cgale_plos_%3EA689420256%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2619536127&rft_id=info:pmid/35025950&rft_galeid=A689420256&rft_doaj_id=oai_doaj_org_article_efd52c420c1f45eea0a15245292f8825&rfr_iscdi=true |